Lyra Therapeutics Debt to Equity

Lyra Therapeutics (LYRA) currently reports a debt-to-equity ratio of -3.93. That is below the Healthcare sector average of 0.27. Use the charts on this page to explore Lyra Therapeutics's debt-to-equity ratio history and peer comparisons.

Lyra Therapeutics's debt-to-equity ratio of -3.93 is lower than the Healthcare sector average of 0.27. That is roughly 1580.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates Lyra Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -3.93, LYRA can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of -3.93, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 0.27. From there, open related valuation or income-statement pages for Lyra Therapeutics, and consider following LYRA for alerts when major investors trade the stock.

Lyra Therapeutics is classified in the Healthcare sector. On debt-to-equity ratio, it currently shows -3.93 versus a sector average near 0.27. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LYRA with unrelated industries.